Aldeyra Therapeutics Inc (STU:137)
€ 4.609 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics, Inc. - Special Call Transcript

Oct 31, 2019 / 12:00PM GMT
Release Date Price: €5.05 (+1.41%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Aldeyra -- the Aldeyra Therapeutics Conference Call. (Operator Instructions).

I would now like to hand the conference over to the company's Chief Financial Officer, Joshua Reed. Thank you, sir. Please go ahead.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Good morning, everyone. With me today are Dr. Todd Brady, President and Chief Executive Officer of Aldeyra; Dr. David Clark, Chief Medical Officer; and Mr. David McMullin, Chief Commercial Officer.

As is summarized on Slide 2, please note that this morning's conference call and the accompanying presentation contain forward-looking statements regarding future events and the future performance of Aldeyra.

Forward-looking statements include statements regarding Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans, research, development and commercial plans or expectations, trends, market sizing, competitive position, industry environment and potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot